Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole

M. Frazzoni, M. Manno, E. De Micheli, V. Savarino

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Acid suppression is the mainstay of therapy in gastro-oesophageal reflux disease. Esomeprazole 40 mg is more effective than lansoprazole 30 mg in healing mucosal lesions in severe erosive reflux oesophagitis. However, data comparing esomeprazole with lansoprazole in patients with complications of gastro-oesophageal reflux disease, such as ulcerative reflux oesophagitis and Barrett's oesophagus, are lacking. Aim: To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease. Methods: Thirty patients with complicated gastro-oesophageal reflux disease (7 with ulcerative reflux oesophagitis and 23 with Barrett's oesophagus), randomly assigned to receive 40 mg esomeprazole (n = 16) or 30 mg lansoprazole (n = 14) once daily, underwent oesophageal 24-h pH monitoring while on therapy. Total, upright diurnal and supine nocturnal percentage acid reflux time were assessed. Results: Esomeprazole was significantly more effective than lansoprazole in decreasing oesophageal acid exposure. Normalisation of both total and supine nocturnal percentage acid reflux time was obtained in 12 of 16 (75%) patients treated with esomeprazole but only in 4 of 14 (28%) cases treated with lansoprazole (p = 0.026). Conclusions: Normalisation of oesophageal acid exposure can be achieved in the majority of complicated gastro-oesophageal reflux disease cases with esomeprazole 40 mg once daily.

Original languageEnglish
Pages (from-to)85-90
Number of pages6
JournalDigestive and Liver Disease
Volume38
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Esomeprazole
Esophageal Diseases
Lansoprazole
Gastroesophageal Reflux
Acids
Peptic Esophagitis
Barrett Esophagus
Therapeutics

Keywords

  • Esomeprazole
  • Gastro-oesophageal reflux disease
  • Lansoprazole
  • Oesophageal pH-monitoring

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease : esomeprazole versus lansoprazole. / Frazzoni, M.; Manno, M.; De Micheli, E.; Savarino, V.

In: Digestive and Liver Disease, Vol. 38, No. 2, 02.2006, p. 85-90.

Research output: Contribution to journalArticle

Frazzoni, M. ; Manno, M. ; De Micheli, E. ; Savarino, V. / Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease : esomeprazole versus lansoprazole. In: Digestive and Liver Disease. 2006 ; Vol. 38, No. 2. pp. 85-90.
@article{4cc88c6aa0a448479b3953148863ddaa,
title = "Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole",
abstract = "Background: Acid suppression is the mainstay of therapy in gastro-oesophageal reflux disease. Esomeprazole 40 mg is more effective than lansoprazole 30 mg in healing mucosal lesions in severe erosive reflux oesophagitis. However, data comparing esomeprazole with lansoprazole in patients with complications of gastro-oesophageal reflux disease, such as ulcerative reflux oesophagitis and Barrett's oesophagus, are lacking. Aim: To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease. Methods: Thirty patients with complicated gastro-oesophageal reflux disease (7 with ulcerative reflux oesophagitis and 23 with Barrett's oesophagus), randomly assigned to receive 40 mg esomeprazole (n = 16) or 30 mg lansoprazole (n = 14) once daily, underwent oesophageal 24-h pH monitoring while on therapy. Total, upright diurnal and supine nocturnal percentage acid reflux time were assessed. Results: Esomeprazole was significantly more effective than lansoprazole in decreasing oesophageal acid exposure. Normalisation of both total and supine nocturnal percentage acid reflux time was obtained in 12 of 16 (75{\%}) patients treated with esomeprazole but only in 4 of 14 (28{\%}) cases treated with lansoprazole (p = 0.026). Conclusions: Normalisation of oesophageal acid exposure can be achieved in the majority of complicated gastro-oesophageal reflux disease cases with esomeprazole 40 mg once daily.",
keywords = "Esomeprazole, Gastro-oesophageal reflux disease, Lansoprazole, Oesophageal pH-monitoring",
author = "M. Frazzoni and M. Manno and {De Micheli}, E. and V. Savarino",
year = "2006",
month = "2",
doi = "10.1016/j.dld.2005.10.001",
language = "English",
volume = "38",
pages = "85--90",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease

T2 - esomeprazole versus lansoprazole

AU - Frazzoni, M.

AU - Manno, M.

AU - De Micheli, E.

AU - Savarino, V.

PY - 2006/2

Y1 - 2006/2

N2 - Background: Acid suppression is the mainstay of therapy in gastro-oesophageal reflux disease. Esomeprazole 40 mg is more effective than lansoprazole 30 mg in healing mucosal lesions in severe erosive reflux oesophagitis. However, data comparing esomeprazole with lansoprazole in patients with complications of gastro-oesophageal reflux disease, such as ulcerative reflux oesophagitis and Barrett's oesophagus, are lacking. Aim: To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease. Methods: Thirty patients with complicated gastro-oesophageal reflux disease (7 with ulcerative reflux oesophagitis and 23 with Barrett's oesophagus), randomly assigned to receive 40 mg esomeprazole (n = 16) or 30 mg lansoprazole (n = 14) once daily, underwent oesophageal 24-h pH monitoring while on therapy. Total, upright diurnal and supine nocturnal percentage acid reflux time were assessed. Results: Esomeprazole was significantly more effective than lansoprazole in decreasing oesophageal acid exposure. Normalisation of both total and supine nocturnal percentage acid reflux time was obtained in 12 of 16 (75%) patients treated with esomeprazole but only in 4 of 14 (28%) cases treated with lansoprazole (p = 0.026). Conclusions: Normalisation of oesophageal acid exposure can be achieved in the majority of complicated gastro-oesophageal reflux disease cases with esomeprazole 40 mg once daily.

AB - Background: Acid suppression is the mainstay of therapy in gastro-oesophageal reflux disease. Esomeprazole 40 mg is more effective than lansoprazole 30 mg in healing mucosal lesions in severe erosive reflux oesophagitis. However, data comparing esomeprazole with lansoprazole in patients with complications of gastro-oesophageal reflux disease, such as ulcerative reflux oesophagitis and Barrett's oesophagus, are lacking. Aim: To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease. Methods: Thirty patients with complicated gastro-oesophageal reflux disease (7 with ulcerative reflux oesophagitis and 23 with Barrett's oesophagus), randomly assigned to receive 40 mg esomeprazole (n = 16) or 30 mg lansoprazole (n = 14) once daily, underwent oesophageal 24-h pH monitoring while on therapy. Total, upright diurnal and supine nocturnal percentage acid reflux time were assessed. Results: Esomeprazole was significantly more effective than lansoprazole in decreasing oesophageal acid exposure. Normalisation of both total and supine nocturnal percentage acid reflux time was obtained in 12 of 16 (75%) patients treated with esomeprazole but only in 4 of 14 (28%) cases treated with lansoprazole (p = 0.026). Conclusions: Normalisation of oesophageal acid exposure can be achieved in the majority of complicated gastro-oesophageal reflux disease cases with esomeprazole 40 mg once daily.

KW - Esomeprazole

KW - Gastro-oesophageal reflux disease

KW - Lansoprazole

KW - Oesophageal pH-monitoring

UR - http://www.scopus.com/inward/record.url?scp=33745401257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745401257&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2005.10.001

DO - 10.1016/j.dld.2005.10.001

M3 - Article

C2 - 16289976

AN - SCOPUS:33745401257

VL - 38

SP - 85

EP - 90

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 2

ER -